Benjamin F. Edwards & Company, Inc. Bei Gene, Ltd. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 872 shares of BGNE stock, worth $160,779. This represents 0.0% of its overall portfolio holdings.
Number of Shares
872
Previous 821
6.21%
Holding current value
$160,779
Previous $128,000
3.13%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.95 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.19 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$955 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$917 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$683 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...